Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rilogrotug
- Development stage
- Phase 3
- Lead developer
- AVEO Oncology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Rilogrotug (AV-380) is an investigational humanized IgG1 monoclonal antibody designed to target and inhibit growth differentiation factor 15 (GDF-15), a pro-inflammatory cytokine associated with weight loss and muscle wasting in cancer patients. By binding to circulating GDF-15, rilogrotug aims to block its signaling, potentially shifting the body's metabolic state from catabolism to anabolism to treat or prevent cancer-induced cachexia. Originally developed by AVEO Pharmaceuticals (now a subsidiary of LG Chem), the drug is currently undergoing early-phase clinical evaluation to assess its safety, pharmacokinetics, and efficacy in reversing cachectic effects.
02
Targets
GDF15 (Growth differentiation factor 15)
Beyond the preview
Go deeper on rilogrotug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rilogrotug.